Anxiety and depression in rheumatologic diseases: the relevance of diagnosis and management

Reumatismo. 2014 Jun 6;66(1):92-7. doi: 10.4081/reumatismo.2014.769.

Abstract

The high prevalence of emotional disorders (anxiety, chronic stress, mood depression) in patients with pain during rheumatologic diseases (particularly fibromyalgia) is closely related to the common pathogenic mechanisms concerning emotions and pain. Therefore a prompt identification of any psychic component of pain, also by means of specific tools, is a must, because it can require an adjustment of the therapeutic approach by combining both an analgesic treatment and antidepressants and/or psychotherapeutic strategies.

Publication types

  • Review

MeSH terms

  • Analgesics / therapeutic use
  • Anti-Anxiety Agents / therapeutic use
  • Anti-Inflammatory Agents / therapeutic use
  • Antidepressive Agents / therapeutic use
  • Antirheumatic Agents / therapeutic use
  • Anxiety / diagnosis
  • Anxiety / drug therapy
  • Anxiety / etiology*
  • Anxiety Disorders / diagnosis
  • Anxiety Disorders / drug therapy
  • Anxiety Disorders / etiology
  • Cytokines / physiology
  • Depression / diagnosis
  • Depression / drug therapy
  • Depression / etiology*
  • Depressive Disorder / diagnosis
  • Depressive Disorder / drug therapy
  • Depressive Disorder / etiology
  • Fibromyalgia / physiopathology
  • Fibromyalgia / psychology
  • Humans
  • Neuroimmunomodulation
  • Neurotransmitter Agents / physiology
  • Pain Management
  • Pain Perception
  • Rheumatic Diseases / drug therapy
  • Rheumatic Diseases / psychology*
  • Stress, Psychological / etiology
  • Stress, Psychological / psychology

Substances

  • Analgesics
  • Anti-Anxiety Agents
  • Anti-Inflammatory Agents
  • Antidepressive Agents
  • Antirheumatic Agents
  • Cytokines
  • Neurotransmitter Agents